BR0210902A - Método de modulação da atividade de canais de cálcio em células cardìacas e reagentes para isso - Google Patents
Método de modulação da atividade de canais de cálcio em células cardìacas e reagentes para issoInfo
- Publication number
- BR0210902A BR0210902A BR0210902-6A BR0210902A BR0210902A BR 0210902 A BR0210902 A BR 0210902A BR 0210902 A BR0210902 A BR 0210902A BR 0210902 A BR0210902 A BR 0210902A
- Authority
- BR
- Brazil
- Prior art keywords
- cardiac
- activity
- calcium channel
- calcium
- modulating
- Prior art date
Links
- 230000000694 effects Effects 0.000 title abstract 6
- 102000003922 Calcium Channels Human genes 0.000 title abstract 5
- 108090000312 Calcium Channels Proteins 0.000 title abstract 5
- 210000002064 heart cell Anatomy 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 4
- 239000003153 chemical reaction reagent Substances 0.000 title abstract 2
- 230000000747 cardiac effect Effects 0.000 abstract 4
- 102000019027 Ryanodine Receptor Calcium Release Channel Human genes 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
- 102000004016 L-Type Calcium Channels Human genes 0.000 abstract 1
- 108090000420 L-Type Calcium Channels Proteins 0.000 abstract 1
- 108010012219 Ryanodine Receptor Calcium Release Channel Proteins 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 229910052791 calcium Inorganic materials 0.000 abstract 1
- 239000011575 calcium Substances 0.000 abstract 1
- 230000001964 calcium overload Effects 0.000 abstract 1
- 230000008878 coupling Effects 0.000 abstract 1
- 238000010168 coupling process Methods 0.000 abstract 1
- 238000005859 coupling reaction Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 108091052345 ryanodine receptor (TC 1.A.3.1) family Proteins 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9453—Cardioregulators, e.g. antihypotensives, antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPR5066A AUPR506601A0 (en) | 2001-05-17 | 2001-05-17 | Method of modulating the activity of calcium channels in cardiac cells and reagents therefor |
| PCT/AU2002/000608 WO2002092119A1 (en) | 2001-05-17 | 2002-05-17 | Method of modulating the activity of calcium channels in cardiac cells and reagents therefor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0210902A true BR0210902A (pt) | 2004-06-08 |
Family
ID=3829046
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0210902-6A BR0210902A (pt) | 2001-05-17 | 2002-05-17 | Método de modulação da atividade de canais de cálcio em células cardìacas e reagentes para isso |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20050049198A1 (enExample) |
| EP (1) | EP1392344A4 (enExample) |
| JP (1) | JP2004535397A (enExample) |
| KR (1) | KR20040002970A (enExample) |
| CN (1) | CN1516596A (enExample) |
| AU (1) | AUPR506601A0 (enExample) |
| BR (1) | BR0210902A (enExample) |
| CA (1) | CA2446839A1 (enExample) |
| NZ (1) | NZ529940A (enExample) |
| WO (1) | WO2002092119A1 (enExample) |
| ZA (1) | ZA200309727B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5370969B2 (ja) * | 2010-02-23 | 2013-12-18 | 国立大学法人金沢大学 | 心筋障害の検査方法 |
| CN101812523B (zh) * | 2010-04-09 | 2012-08-22 | 广州益善生物技术有限公司 | Ryr1基因snp检测特异性引物、液相芯片和检测方法 |
| CN109010799B (zh) * | 2018-07-09 | 2021-07-06 | 沣潮医药科技（上海）有限公司 | RyR2蛋白或RyR2重组蛋白在制备抗心力衰竭药物中的用途 |
| CN109306011B (zh) * | 2018-09-27 | 2021-08-03 | 中国人民解放军第二军医大学 | 靶向RyR2蛋白的胞内纳米抗体在制备抗心力衰竭药物中的用途 |
| CN119876003B (zh) * | 2025-01-21 | 2026-04-24 | 深圳大学 | 一种肌质网钙泵囊泡的分离纯化方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5691310A (en) * | 1987-09-29 | 1997-11-25 | Vesely; David L. | Methods of treatment using proANF peptides |
| DE4110785A1 (de) * | 1991-04-04 | 1992-10-08 | Bayer Ag | Gewebe-spezifische humane neuronale calcium-kanal-subtypen und deren verwendung |
| AU1890092A (en) * | 1991-04-18 | 1992-11-17 | Indiana University Foundation | Novel ester derivatives of ryanodine and dehydroryanodine |
| CA2385047A1 (en) * | 1999-09-22 | 2001-03-29 | Ann H. Cornell-Bell | Uses of kappa-conotoxin pviia |
| GB0005124D0 (en) * | 2000-03-03 | 2000-04-26 | Cellpep Sa | Maurocalcin,analogues thereof and their therapeutical uses |
| US7105489B2 (en) * | 2002-01-22 | 2006-09-12 | Amylin Pharmaceuticals, Inc. | Methods and compositions for treating polycystic ovary syndrome |
-
2001
- 2001-05-17 AU AUPR5066A patent/AUPR506601A0/en not_active Abandoned
-
2002
- 2002-05-17 BR BR0210902-6A patent/BR0210902A/pt not_active IP Right Cessation
- 2002-05-17 CA CA002446839A patent/CA2446839A1/en not_active Abandoned
- 2002-05-17 CN CNA028120566A patent/CN1516596A/zh active Pending
- 2002-05-17 US US10/478,112 patent/US20050049198A1/en not_active Abandoned
- 2002-05-17 WO PCT/AU2002/000608 patent/WO2002092119A1/en not_active Ceased
- 2002-05-17 EP EP02721869A patent/EP1392344A4/en not_active Withdrawn
- 2002-05-17 KR KR10-2003-7014989A patent/KR20040002970A/ko not_active Withdrawn
- 2002-05-17 NZ NZ529940A patent/NZ529940A/en unknown
- 2002-05-17 JP JP2002589036A patent/JP2004535397A/ja not_active Withdrawn
-
2003
- 2003-12-15 ZA ZA200309727A patent/ZA200309727B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200309727B (en) | 2005-08-01 |
| CN1516596A (zh) | 2004-07-28 |
| KR20040002970A (ko) | 2004-01-07 |
| AUPR506601A0 (en) | 2001-06-07 |
| NZ529940A (en) | 2006-08-31 |
| US20050049198A1 (en) | 2005-03-03 |
| CA2446839A1 (en) | 2002-11-21 |
| WO2002092119A1 (en) | 2002-11-21 |
| EP1392344A1 (en) | 2004-03-03 |
| EP1392344A4 (en) | 2005-09-21 |
| JP2004535397A (ja) | 2004-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0312785A (pt) | Tratamento de desordens relacionadas a tnf(alfa) | |
| DK1094816T3 (da) | Biphenylsulfonamider som dobbelte angiotensin-endothelin-receptorantagonister | |
| TR199800585T2 (xx) | COX-2 �nhibit�rleri Olarak (Metils�lfonil)Fenil-2-(5H)-Furanonlar. | |
| BRPI0414930A (pt) | compostos e composições como inibidores de proteìnas cinases | |
| BRPI0411319A (pt) | compostos terapeuticamente ativos e sua utilização | |
| NO331024B1 (no) | Anvendelse av risendroninsyre for forebygging eller behandling av osteoporose | |
| NO20042964L (no) | Spiroazasykliske forbindelser som monoaminreseptormodulatorer | |
| BRPI0410348A (pt) | compostos e usos dos mesmos na modulação de amilóide-beta | |
| BR0116370A (pt) | Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente. | |
| PT1107794E (pt) | Composicoes terapeuticass para tratamento da hipersecrecao de muco | |
| BR0313562A (pt) | derivados de indol ou benzimidazol para a modulação da ikb-cinase | |
| AU5624699A (en) | Use of 5ht-6 antagonists | |
| BR0011172A (pt) | Derivados do 4,5-diaril-3(2h)-furanona como inibidores de cliclooxigenase-2 | |
| EP1605752A4 (en) | COMPOUNDS, COMPOSITIONS AND METHODS | |
| AU2002345490A1 (en) | Hccss as modifiers of the p53 pathway and methods of use | |
| MXPA02007099A (es) | Compuestos de tiazola, imidazola y oxazola y tratamientos de desordenes asociados con la maduracion de la proteina. | |
| BR0309278A (pt) | Composto, composição, métodos para modular a atividade da cinesina ksp, para inibir a ksp, para o tratamento de uma doença proliferativa celular, e, uso de um composto | |
| DK0778890T3 (da) | DNA, som koder for en human calciumkanal-alpha-1E-underenhed | |
| NO20091243L (no) | Titreringsskjema for bifeprunox for behandling av schizofreni og kits for anvendelse deri | |
| BR0307903A (pt) | derivados de arilsulfona | |
| NO20014241D0 (no) | C16-umettede FP-selektive prostaglandinanaloger | |
| NO20015247L (no) | Glysinspaltingssysteminhibitorer som potensielle antipsykotika | |
| BR9813996A (pt) | 2-arilbenzo[b]tiofenos úteis para o tratamento de sìndrome da privação de estrogênio | |
| DE69510545D1 (de) | Cck oder gastrin modulierende 5-heterocyclicyl-1,5-benzodiazepine | |
| NO980251L (no) | Behandling av konsentrasjonssvikt/hyperaktivitetsforstyrrelse |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A E 8A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2060 DE 29/06/2010. |